EP Wealth Advisors LLC Decreases Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

EP Wealth Advisors LLC lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,799 shares of the medical equipment provider’s stock after selling 160 shares during the period. EP Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $204,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC raised its position in Zimmer Biomet by 0.5% in the first quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider’s stock valued at $2,903,000 after purchasing an additional 118 shares during the period. Curbstone Financial Management Corp raised its holdings in shares of Zimmer Biomet by 3.4% in the 1st quarter. Curbstone Financial Management Corp now owns 4,266 shares of the medical equipment provider’s stock valued at $483,000 after buying an additional 140 shares during the period. Brooklyn Investment Group increased its holdings in Zimmer Biomet by 45.9% during the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 145 shares during the period. Roberts Wealth Advisors LLC increased its holdings in Zimmer Biomet by 0.8% during the 1st quarter. Roberts Wealth Advisors LLC now owns 18,497 shares of the medical equipment provider’s stock worth $2,093,000 after purchasing an additional 152 shares during the period. Finally, Wesbanco Bank Inc. increased its holdings in Zimmer Biomet by 0.8% during the 1st quarter. Wesbanco Bank Inc. now owns 20,012 shares of the medical equipment provider’s stock worth $2,265,000 after purchasing an additional 163 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Royal Bank Of Canada increased their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Evercore ISI dropped their price objective on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a report on Tuesday, July 8th. UBS Group increased their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a report on Friday, August 8th. Raymond James Financial increased their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Finally, Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $111.00.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Down 1.5%

Zimmer Biomet stock opened at $102.33 on Thursday. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72. The stock has a 50 day moving average of $99.06 and a two-hundred day moving average of $99.63. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $20.27 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 2.05 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same period last year, the firm earned $2.01 EPS. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.